Next Article in Journal
Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ
Next Article in Special Issue
Developing Combined HIV Vaccine Strategies for a Functional Cure
Previous Article in Journal
Trust in Vaccines: Why It Takes More than Good Faith
Previous Article in Special Issue
Isotype Diversification of IgG Antibodies to HIV Gag Proteins as a Therapeutic Vaccination Strategy for HIV Infection
Vaccines 2013, 1(3), 348-366; doi:10.3390/vaccines1030348

An HIV Vaccine for South-East Asia—Opportunities and Challenges

1 Vaccine Trial Center, Faculty of Tropical Medicine, Mahidol University, 420/6 Rajvithi Road, Bangkok 10400, Thailand 2 Department of Disease Control, Ministry of Public Health, Nonthaburi 11000, Thailand 3 Department of Retrovirology, US Army Medical Component, Armed Forces Institute of Medical Sciences (AFRIMS), 315/6 Rajvithi Road, Bangkok 10400, Thailand 4 Military HIV Research Program (MHRP), Walter Reed Army Institute of Research, 6720-A Rockledge Drive, Suite 400, Bethesda, MD 20817, USA These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 3 June 2013 / Revised: 25 July 2013 / Accepted: 5 August 2013 / Published: 14 August 2013
(This article belongs to the Special Issue HIV Vaccines)
View Full-Text   |   Download PDF [510 KB, uploaded 14 August 2013]


Recent advances in HIV vaccine development along with a better understanding of the immune correlates of risk have emerged from the RV144 efficacy trial conducted in Thailand. Epidemiological data suggest that CRF01_AE is still predominant in South-East Asia and is spreading in China with a growing number of circulating recombinant forms due to increasing human contact, particularly in large urban centers, tourist locations and in sites of common infrastructure. A vaccine countering CRF01_AE is a priority for the region. An Asia HIV vaccine against expanding B/E or BCE recombinant forms should be actively pursued. A major challenge that remains is the conduct of efficacy trials in heterosexual populations in this region. Men who have sex with men represent the main target population for future efficacy trials in Asia. Coupling HIV vaccines with other prevention modalities in efficacy trials might also be envisaged. These new avenues will only be made possible through the conduct of large-scale efficacy trials, interdisciplinary teams, international collaborations, and strong political and community commitments.
Keywords: HIV vaccines; RV144; correlates of risk; efficacy trials; HIV-1 subtypes; Men who have sex with men; South-East Asia; Thailand; Myanmar; China HIV vaccines; RV144; correlates of risk; efficacy trials; HIV-1 subtypes; Men who have sex with men; South-East Asia; Thailand; Myanmar; China
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Pitisuttithum, P.; Rerks-Ngarm, S.; O'Connell, R.J.; Kim, J.H.; Excler, J.-L. An HIV Vaccine for South-East Asia—Opportunities and Challenges. Vaccines 2013, 1, 348-366.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert